Stanford Medicine reported a preclinical intranasal vaccine that protected mice against multiple respiratory viruses, bacterial pathogens and even an allergen by combining innate and adaptive immune stimulation. Led by Bali Pulendran and published in Science, the study showed durable lung protection against SARS‑CoV‑2, several coronaviruses, Staphylococcus aureus, Acinetobacter baumannii and house dust mite allergen in murine models. The vaccine’s mechanism integrates mucosal immunity and systemic memory to sustain broad, non‑antigen‑specific protection in the lungs. Researchers cautioned the work is preclinical and emphasized careful translational steps to assess safety and specificity in humans, but noted the approach could shift thinking about preparedness for seasonal and emerging respiratory threats.